Clinical trial No longer in our active list Phase 3 Interventional Ages 18 and up Men only

Investigating PF-06821497 for men with advanced prostate cancer

Official title: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

Run by Pfizer · NCT06551324 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing if a new medicine called PF-06821497, when combined with enzalutamide, can help men with advanced prostate cancer live longer without their cancer getting worse compared to standard treatments.

More Metastatic Castration-resistant Prostate Cancer (mCRPC) trials Research outlook What's coming for Metastatic prostate cancer: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment600 (estimated)
SponsorPfizer
Industry-sponsored
Drugs / interventionschemotherapy
Locations175 sites (Homewood, Alabama and 174 other locations)
Trial IDNCT06551324 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are men with histologically confirmed adenocarcinoma of the prostate who have metastatic disease and have shown disease progression after treatment with abiraterone acetate.

Probably not a fit

Patients with small cell features of prostate cancer or those with significant comorbidities that may interfere with participation may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and effectiveness of the investigational medicine PF-06821497 when combined with enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC) who have previously been treated with abiraterone acetate. Participants will be randomly assigned to receive either the combination treatment or a physician's choice of second-line therapy, which may include enzalutamide or docetaxel. The primary goal is to assess the radiographic progression-free survival (rPFS) of the combination therapy compared to the standard treatments.

Why it matters

Potential benefit: If successful, this study could provide a new effective treatment option for men with advanced prostate cancer who have limited options after prior therapies.

How similar studies have gone: Other studies have shown promise with similar combination therapies in treating advanced prostate cancer, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.
* Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
* Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required.
* Eastern Cooperate Oncology Group (ECOG) performance status 0 - 2, with life expectancy of at least 6 months as assessed by the investigator.

Exclusion Criteria:

* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may make the participant inappropriate for the study.
* Know history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery.
* Clinically significant cardiovascular disease.
* Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure.
* Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy (i.e. 177Lu-PSMA-617, radium 223), androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment, with the following exceptions:

  1. Treatment with first-generation antiandrogen agents, if discontinued prior to first dose of study intervention.
  2. Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion.
* Previous administration with an investigational product within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is shorter).
* Inadequate organ function.

Where it's running

  • Urology Centers of Alabama
    Homewood, Alabama, United States
    Recruiting
  • Arizona Urology Specialists- Provide ICF for Review Only
    Tucson, Arizona, United States
    Recruiting
  • Arizona Urology Specialists (AUS)-Orange Grove
    Tucson, Arizona, United States
    Recruiting
  • Sutter Santa Rosa
    Santa Rosa, California, United States
    Recruiting
  • Colorado Clinical Research
    Lakewood, Colorado, United States
    Recruiting
  • Florida Cancer Specialists
    Bonita Springs, Florida, United States
    Recruiting
Show 44 more locations
  • Florida Cancer Specialists
    Bradenton, Florida, United States
    Recruiting
  • Florida Cancer Specialists
    Cape Coral, Florida, United States
    Recruiting
  • Florida Cancer Specialists
    Fort Myers, Florida, United States
    Recruiting
  • Florida Cancer Specialists
    Fort Myers, Florida, United States
    Recruiting
  • Florida Cancer Specialists
    Naples, Florida, United States
    Recruiting
  • Florida Cancer Specialists
    Port Charlotte, Florida, United States
    Recruiting
  • Florida Cancer Specialists
    Sarasota, Florida, United States
    Recruiting
  • Florida Cancer Specialists
    Venice, Florida, United States
    Recruiting
  • Duly Health and Care
    Hinsdale, Illinois, United States
    Recruiting
  • Duly Health And Care
    Lisle, Illinois, United States
    Recruiting
  • NextStage Clinical Research-Chicago-(04)
    Lisle, Illinois, United States
    Recruiting
  • Duly Health and Care
    Westmont, Illinois, United States
    Recruiting
  • AtlantiCare
    Egg Harbor Township, New Jersey, United States
    Recruiting
  • Keystone Urology Specialists
    Lancaster, Pennsylvania, United States
    Recruiting
  • SCRI Oncology Partners
    Nashville, Tennessee, United States
    Recruiting
  • USA Clinical Trials
    San Antonio, Texas, United States
    Recruiting
  • Huntsman Cancer Institute
    Salt Lake City, Utah, United States
    Recruiting
  • Centro de Urología (CDU)
    Caba, Buenos Aires, Argentina
    Recruiting
  • Hospital Sirio Libanes
    Capital Federal, Buenos Aires, Argentina
    Recruiting
  • Imagenes Mdq
    Mar del Plata, Buenos Aires, Argentina
    Recruiting
  • Instituto de Investigaciones Clínicas Mar del Plata
    Mar del Plata, Buenos Aires, Argentina
    Recruiting
  • Centro Medico Privado CEMAIC
    Capital, Córdoba, Argentina
    Recruiting
  • Imaxe
    Buenos Aires, Argentina
    Recruiting
  • Asociación de Beneficencia Hospital Sirio Libanés
    Buenos Aires, Argentina
    Recruiting
  • Icon Cancer Centre Wesley
    Auchenflower, Queensland, Australia
    Recruiting
  • Monash Health
    Clayton, Victoria, Australia
    Recruiting
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria, Australia
    Recruiting
  • Hospital São Lucas da PUCRS
    Porto Alegre, RIO Grande DO SUL, Brazil
    Recruiting
  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
    Santo André, SÃO Paulo, Brazil
    Recruiting
  • Hospital Alemao Oswaldo Cruz
    Sao Paulo, SÃO Paulo, Brazil
    Recruiting
  • Instituto do Cancer Arnaldo Vieira de Carvalho
    São Paulo, Brazil
    Recruiting
  • IBCC - Núcleo de Pesquisa e Ensino
    São Paulo, Brazil
    Recruiting
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing, China
    Recruiting
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
    Recruiting
  • Lanzhou university second hospital
    Lanzhou, Gansu, China
    Recruiting
  • The Second Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi, China
    Recruiting
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
  • Hunan Cancer Hospital
    Changsha, Hunan, China
    Recruiting
  • Nantong Tumor Hospital
    Nantong, Jiangsu, China
    Recruiting
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
    Recruiting
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
    Recruiting
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
    Recruiting
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi, China
    Recruiting
  • Shaanxi Provincial People' Hospital
    Xi'an, Shaanxi, China
    Recruiting

+125 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.